Semaglutide

A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management that reduces appetite and improves glycemic control.

Also known as: Ozempic, Wegovy, Rybelsus

Regulatory Status

FDA-Approved

Classification date: 2017-12-05

Compounding: Not currently available for compounding

Evidence Summary

Strong100 human studies published

Key Studies

How It Works

Semaglutide is an acylated GLP-1 analog with 94% homology to native GLP-1 and an extended half-life of approximately 7 days due to albumin binding. It activates GLP-1 receptors in the pancreas to enhance glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying. Centrally, it acts on hypothalamic appetite centers to reduce food intake, producing sustained weight loss of 15-17% of body weight in clinical trials.

Common Applications

Type 2 diabetes managementChronic weight management (BMI >= 27 with comorbidity or BMI >= 30)Cardiovascular risk reduction in patients with diabetesAppetite suppression and metabolic improvement

Safety & Considerations

Common side effects include nausea, vomiting, diarrhea, and constipation, which typically decrease over time. Carries a boxed warning for thyroid C-cell tumors (observed in rodents). Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Risk of pancreatitis, gallbladder disease, and hypoglycemia (especially with sulfonylureas or insulin). Requires dose escalation to reduce GI side effects.

Available Through Our Network

This peptide is available through our partner pharmacies with a valid prescription.

Coming Soon →

Regulatory classifications can change rapidly. The information shown here was last verified on 2017-12-05. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.